SSBD:database

Detail of Fig1E_SARS-CoV-2_6dpi_ibd-LoC

Sayaka Deguchi, Kaori Kosugi, Rina Hashimoto, Ayaka Sakamoto, Masaki Yamamoto, Rafal P Krol, Peter Gee, Ryosuke Negoro, Takeshi Noda, Takuya Yamamoto, Yu-Suke Torisawa, Miki Nagao, Kazuo Takayama (2023) Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips., PNAS nexus, Volume 2, Number 3, pp. pgad029

Published in 2023 Mar (Electronic publication in March 7, 2023, midnight )

• doi: 10.1093/pnasnexus/pgad029
• pmid: 36896132
  

(Abstract) SARS-CoV-2 induces severe organ damage not only in the lung but also in the liver, heart, kidney, and intestine. It is known that COVID-19 severity correlates with liver dysfunction, but few studies have investigated the liver pathophysiology in COVID-19 patients. Here, we elucidated liver pathophysiology in COVID-19 patients using organs-on-a-chip technology and clinical analyses. First, we developed liver-on-a-chip (LoC) which recapitulating hepatic functions around the intrahepatic bile duct and blood vessel. We found that hepatic dysfunctions, but not hepatobiliary diseases, were strongly induced by SARS-CoV-2 infection. Next, we evaluated the therapeutic effects of COVID-19 drugs to inhibit viral replication and recover hepatic dysfunctions, and found that the combination of anti-viral and immunosuppressive drugs (Remdesivir and Baricitinib) is effective to treat hepatic dysfunctions caused by SARS-CoV-2 infection. Finally, we analyzed the sera obtained from COVID-19 patients, and revealed that COVID-19 patients, who were positive for serum viral RNA, are likely to become severe and develop hepatic dysfunctions, as compared with COVID-19 patients who were negative for serum viral RNA. We succeeded in modeling the liver pathophysiology of COVID-19 patients using LoC technology and clinical samples.